Johnson & Johnson has announced that it will invest more than $500m over the next four years in research and development programmes focused on HIV and tuberculosis, with an aim to eliminate both diseases by 2030.
Johnson & Johnson has announced that it will invest more than $500m over the next four years in research and development programmes focused on HIV and tuberculosis, with an aim to eliminate both diseases by 2030.